SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Brawn Biotech Ltd

BSE: 530207 NSE: ISIN: INE899B01015
  |   Sector:  Miscellaneous   |   Industry:  Trading

Snapshot

Q.1 Which industry/sub-sector does Brawn Biotech Ltd belong to?
Brawn Biotech Ltd belongs to the Miscellaneous sector, operating specifically within the Trading segment.
Q.2 Is Brawn Biotech Ltd a good quality company?
Brawn Biotech Ltd is a quality company, based on a 10 year financial track record.
Q.3 Is Brawn Biotech Ltd undervalued or overvalued?
Brawn Biotech Ltd appears Fair, as its key valuation ratios are in line with their past averages.
Q.4 Is Brawn Biotech Ltd a good buy now?
Brawn Biotech Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Brawn Biotech Ltd?
Brawn Biotech Ltd revenue growth is -18.3% for FY-2025 , which is above its 5 year CAGR of -23% , indicating faster growth.
Q.2 Gross Profit margin of Brawn Biotech Ltd?
Brawn Biotech Ltd Gross profit margin which is the profit after deduction of direct costs, is -12.5% for FY-2025 , which is below its 5 year median of -8.8% , indicating decreasing margins.
Q.3 Operating Profit Margin of Brawn Biotech Ltd?
Brawn Biotech Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is -13.16% for FY-2025 , which is below its 5 year median of -8.88% indicating decreasing margins.
Q.4 Net Profit Margin of Brawn Biotech Ltd?
Brawn Biotech Ltd Net Profit Margin is -12.92% for FY-2025 , is below with its 5 year median of -7.56%, indicating decreasing margins.
Current Level Historic Median
Gross Profit Margin -12.5 -8.8
Operating Profit Margin -13.16 -8.88
Net Profit Margin -12.92 -7.56
Q.5 Return on Asset of Brawn Biotech Ltd?
Brawn Biotech Ltd Return on Asset is -10.2%, which is below its 5 year historical median of -8.75%, indicating deteriorated asset utilization efficiency.
Q.6 Return on Equity (ROE) of Brawn Biotech Ltd?
Brawn Biotech Ltd Return on equity is -41.3% for FY-2025 , which is below its historical median of -20.53%, indicating the business is making worse use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Brawn Biotech Ltd?
Brawn Biotech Ltd Return on capital employed is -42.59% for FY-2025 , which is below its estimated weighted average cost of capital(WACC) 14%, indicating value preservation.
Q.8 Cash conversion cycle of Brawn Biotech Ltd?
Brawn Biotech Ltd Cash conversion cycle is 185 days, above its historical median of 99 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 0.79 1.16
ROE -41.3 -20.53
ROCE -42.59 -25.66
Cash Conversion Cycle 185 days 99 days
Q.9 Debt to Equity ratio of Brawn Biotech Ltd?
Brawn Biotech Ltd Debt-to-Equity ratio is 0.00 , which is lower with the industry average of 0.03 , indicating lower debt levels in the industry.
Q.10 Debt to cash flow from operations of Brawn Biotech Ltd?
Brawn Biotech Ltd Debt to cash flow from operations is 0 , which is at a healthy level, indicating the business is able to service its debt comfortably.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Brawn Biotech Ltd?
Promoters hold 52.94% of the Brawn Biotech Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Brawn Biotech Ltd vs industry peers?
Brawn Biotech Ltd revenue CAGR is -22.96% , compared to the industry median CAGR of 0% , indicating stable growth and maintaining its market share.
Profit Metrics
Current Level Industry Median
Revenue 13.5 13.3
Gross Profit -1.7 0.4
Operating Profit -1.8 0
Net Profit -1.7 0.3
Operating Efficiency
Current Level Industry Median
Asset Turnover 0.79 0.5
ROE -41.3 2.03
ROCE -42.59 3.6
Cash Conversion Cycle (days) 184.85 41

Valuation & price assessment

Q.1 Stock return of Brawn Biotech Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of -7.9% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price -7.9% -2.2% 6.6% 16.9%
Q.3 Valuation ratios of Brawn Biotech Ltd vs historical?
The current P/E is similar that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings - 0.00 21.75
Price to Book 1.64 0.00 1.55
Price to Sales 0.36 0.16 1.87
EV to EBITDA -541.42 0.00 13.67

Check more companies

1. Aditya Infotech
2. Aegis Logistics
3. Redington
4. RRP Semiconductor
5. Honasa Consumer
6. Cello World
7. Lloyds Enterprises
8. MMTC
9. Jeena Sikho Life
10. SG Mart
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×